Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 113

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 113
---
 if we do, we will be subject to the risk of doing business internationally. We operate and expect to operate in various countries, and we may not be able to market our products in, or develop new products successfully for, these markets. We may also encounter other risks of doing business internationally including but not limited to: •unexpected changes in, or impositions of, legislative or regulatory requirements; •efforts to develop an international sales, marketing and distribution organization may increase our expenses, divert our management’s attention from the acquisition or development of drug candidates or cause us to forgo profitable licensing opportunities in these geographies; •the occurrence of economic weakness, including inflation or political instability; •the effects of applicable non -U.S. tax structures and potentially adverse tax consequences; •differences in protection of our IP rights including patent rights of other parties; •the burden of complying with a variety of foreign laws including difficulties in effective enforcement of contractual provisions; •delays resulting from difficulty in obtaining export licenses, tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collection and potentially adverse tax treatment; and •production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. In addition, we are subject to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes in diplomatic and trade relationships, which could affect, among other things, customers’ inventory levels and consumer purchasing, which could cause our results to fluctuate and our net sales to decline. The occurrence of any one or more of these risks of doing business internationally, individually or in the aggregate, could materially and adversely affect our business and results of operations. If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, IP rights, technology or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to: •increase in operating expenses and cash requirements; •the assumption of additional indebtedness or contingent liabilities; •the issuance of our equity securities; 47 •assimilation of operations, IP and products of an acquired company, including difficulties associated with integrating new personnel; •the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; •retention of key employees, the loss of key personnel, and uncertainties in